Therapy for transthyretin-associated amyloidosis
CENTELLAS CASADO MARC (ES)
INSA BORONAT RAÚL (ES)
REIG BOLAÑO NURIA (ES)
GAVALDÀ BATALLA NÚRIA (ES)
- Priority:2011/10/24
- Grant:2017/04/04
CENTELLAS CASADO MARC (ES)
INSA BORONAT RAÚL (ES)
REIG BOLAÑO NURIA (ES)
GAVALDÀ BATALLA NÚRIA (ES)
- AU-2012327275-A1
- AU-2012327275-A2
- AU-2012327275-B2
- AU-2017202670-A1
- AU-2017202670-B2
- BR-112014009322-A2
- BR-112014009322-A8
- BR-112014009322-B1
- CA-2852808-A1
- CA-2852808-C
- CL-2014000893-A1
- CN-103889407-A
- CN-103889407-B
- CY-1118151-T1
- EP-2770988-A1
- EP-2770988-B1
- ES-2593038-T3
- HK-1198432-A1
- IL-231907-A0
- IL-231907-B
- JP-2014530842-A
- JP-6068484-B2
- KR-102017354-B1
- KR-20140090161-A
- MX-2014004863-A
- MX-347784-B
- NZ-623267-A
- PL-2770988-T3
- PT-2770988-T
- RU-2014114930-A
- RU-2017119539-A
- RU-2017119539-A3
- RU-2623062-C2
- RU-2747536-C2
- SG-10201609933W-A
- SG-11201401215V-A
- US-10045956-B2
- US-10449169-B2
- US-10786473-B2
- US-11564899-B2
- US-2014296188-A1
- US-2017304243-A1
- US-2019091188-A1
- US-2020138760-A1
- US-2020390733-A1
- US-9610270-B2
- WO-2013060668-A1
- ZA-201402546-B
A61K31/353 (inventive)
A61K31/42 (inventive, first)
A61K31/192 (inventive)
A61K31/165 (inventive)
A61K31/198 (inventive)
A61K31/12 (inventive)
A61K31/423 (inventive)
A61K45/06 (inventive)
A61K31/603 (inventive)
A61P43/00 (inventive)
A61P25/28 (inventive)
A61P25/00 (inventive)
A61K45/06 (inventive)
A61K31/353 (inventive)
A61K31/423 (inventive)
A61K31/192 (inventive)
A61K31/603 (inventive)
A61K31/198 (inventive, first)
A61K9/20
A61K31/12 (inventive)
A61K31/138
A61K2300/00
- WO-9512815-A1 (APP)
- WO-9827972-A2 (APP)
- WO-0222551-A1 (APP)
- WO-03013442-A2 (APP)
- WO-03063880-A1 (APP)
- WO-2005079795-A2 (APP)
- WO-2005094218-A2 (APP)
- WO-2005113523-A1 (APP)
- WO-2005112913-A1 (APP)
- US-2005282780-A1 (APP)
- WO-2006026555-A2 (APP)
- GB-2429645-A (APP)
- CN-1953746-A (APP)
- WO-2008013764-A2 (APP)
- CN-101198598-A (APP)
- RU-2394570-C2 (APP)
- US-2010249233-A1 (APP)
- WO-2011110396-A1 (APP)
- RU-2428987-C2 (APP)
- Benson, "Amyloidosis," in Scriver et al. "The Metabolic and Molecular Basis of Inherited Disease," McGraw-Hill Medical, 8th Edition, pp. 5345-5378 (2001). (APP)
- Di Giovanni et al. "Entacapone and Tolcapone, Two Catechol-O-Methyltransferase Inhibitors, Block Fibril Formation of Alpha-Synuclein and Beta-Amyloid and Protect Against Amyloid-Induced Toxicity," J. Biol. Chem., vol. 285, pp. 14941-14954 (2010). (APP)
- Dolado et al. "Kinetic Assay for High-Throughput Screening of In Vitro Transthyretin Amyloid Fibrillogenesis Inhibitors", J. Comb. Chem., vol. 7, pp. 246-252 (2005). (APP)
- Ferreira et al. "Natural Polyphenols Inhibit Different Steps of the Process of Transthyretin (TTR) Amyloid Fibril Formation," FEBS Lett., vol. 585, pp. 2424-2430 (2011). (APP)
- Ferreira et al. FEBS Lett., vol. 583, pp. 3569-3576 (2009). (APP,APP)
- Gales et al. "Human Transthyretin in Complex with Iododiflunisal: Structural Features Associated with a Potent Amyloid Inhibitor", Blochem J., vol. 388, pp. 615-621 (2005). (APP)
- Gupta et al., "Design of Mechanism-Based Inhibitors of Transthyretin Amyloidosis: Studies with Biphenyl Ethers and New Structural Templates," J, Med. Chem., 50, pp. 5589-5599 (2007). (APP)
- Hurshman et al. "Transthyretin Aggregation under Partially Denaturing Conditions is a Downhill Polymerization," Biochemistry, vol. 43, pp. 7365-7381 (2004). (APP)
- Idicula-Thomas et al. "Protein Aggregation: A Perspective from Amyloid and Inclusion-body Formation," Current Science, vol. 92, pp. 758-767 (2007). (APP)
- International Perliminary Report on Patentability and Written Opinion of the International Searching Authorirty corresponding to International Application No. PCT/EP2012/070945 dated Apr. 29, 2014. (APP,APP)
- International Search Report corresponding to PCT/EP2012/070945 dated Feb. 18, 2013. (APP,APP)
- Klabunde et al. "Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors", Nature Structural Biology, vol. 7, pp. 312-321 (2000). (APP)
- Lee et al. "Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomer," Nature Chemical Biology, vol. 7, pp. 602-609 (2011). (APP)
- Männistö et al. "Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors", Pharmacol. Rev., vol. 51, pp. 593-628 (1999). (APP)
- Mannisto et al. "Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors", vol. 51, pp. 593-628 (1999). (APP)
- Nippon Rinsho (Japanese journal of clinical medicine), vol. 49, No. 4, pp. 10-17 (Apr. 1991). (APP,APP)
- Translation of Office Action corresponding to Russian Patent Application No. 2014114930 dated Sep. 5, 2016. (APP,APP)
- Wood et al. "α-Synuclein Fibrillogenesis is Nucleation-dependent: Implications for the Pathogenesis of Parkinson's Disease," J. Biol. Chem., vol. 274, No. 28, pp. 19509-19512 (1999). (APP)
- US-10045956-B2 (SEA)
- US-2019091188-A1 (A) (SEA)
- US-10449169-B2 (SEA)
- US-2020138760-A1 (A) (SEA)
- US-10786473-B2 (SEA)
- US-11564899-B2 (SEA)
- Google PatentsLICENSE"Google Patents Research Data" by Google, based on data provided by IFI CLAIMS Patent Services and OntoChem, is licensed under a Creative Commons Attribution 4.0 International License.https://creativecommons.org/licenses/by/4.0/legalcode
- PubChem